DNA

Synthetic biology company Evonetix has appointed a new Chief Executive Officer (CEO) to support the company’s next phase of product development.   The company has appointed Colin McCracken as CEO with immediate effect. McCracken has over 20 years of experience and will support Evonetix in the development and commercialisation of its semiconductor-based DNA synthesis platform.  Prior […]

Synthetic biology company Evonetix has been granted a European patent covering its unique Binary Assembly method for gene synthesis.  The patent forms part of the company’s plan to simplify gene synthesis for users and enable a new generation of in-lab DNA synthesis platforms.  Evonetix’s novel semiconductor-based synthesis chip uses precise temperature control to manage the […]

Integrated DNA Technologies (IDT) has released Alt-R HDR Donor Blocks, a solution for increasing homology-directed repair (HDR) rates in large fragment knock-in experiments.   How does Alt-R HDR work?  The Alt-R HDR Donor Blocks incorporate advanced chemical modifications to boost the HDR rates of large genomic changes and insertions, and significantly reduce the occurrence of non-homologous […]

Evonetix is reimagining biology. Dr Vijay Narayan, Head of Physics, Dr Stuart Crosby, Head of Synthetic Chemistry, and Daniel Bygrave, Principal Software Engineer, offer insight into the technology being developed by the company and its relevance for researchers.  “I have always been intrigued by interdisciplinary environments,’ says Dr Vijay Narayan, Head of Physics, Evonetix. “This is what initially drew me to […]

Listen to this article on the DDW Podcast: Rosie Bryan & Carlos le Sage, Horizon Discovery, explain how CRISPR-Cas9 technology has become a gold standard for functional genomics.  While efforts in the cancer genomics field have uncovered the mutational landscapes in tumours covering many types of cancer, the functional contribution of the mutated genes to cancer onset and […]

NovAliX, a CRO specialising in drug research and development, has partnered with Sanofi for the development of new DNA-Encoded Libraries (DELs), allowing the partners to design both general and focused chemical libraries, and carry out screening activities to identify new and useful chemical structures.  Why is this useful?  DEL technology can be used to support the drug […]

This is the latest episode of the free DDW podcast, “Building on current drug discovery methods”. It covers two narrated article written for Volume 22, Issue 2 – Spring 2021 of DDW and read aloud by Megan Thomas. The articles are called “The new synthesis: How synthetic DNA technology is changing drug discovery” and “In […]

Target class-specific libraries mean you need to screen less to identify high-quality antibodies. Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates. Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics. However, only a few general-purpose libraries have been commercially available for drug discovery. As a result, most approved library-derived antibodies originate […]

Flerie Invest led a syndicate of investors in the $52 million acquisition of Cobra Biologics, Charles River Laboratories’ DNA and protein manufacturing subsidiary in Sweden. The new entity, NorthX Biologics, will take over and expand the facility, which is equipped to provide GMP-grade plasmid DNA and technical protein manufacture at commercial scale.   Ibrahim Baylan, the Swedish Minister for Business, […]

DNA Script has raised $165 million in a Series C financing led by Coatue Management and Catalio Capital Management, whose representatives have joined as board observers. The new funds will be used to accelerate expansion and commercialisation of the company’s SYNTAX Platform and broaden the portfolio of products powered by EDS.  DNA Script released the SYNTAX System in June 2020, a […]